British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...

It is worth considering GSK (GSK), which belongs to the Zacks Medical - Biomedical and Genetics industry. When looking at the last two reports, this drug developer has recorded a strong streak of ...

GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware ...

Bullish option flow detected in GSK (GSK) Pharma with 5,714 calls trading, 4x expected, and implied vol increasing over 5 points to 42.48%. Apr-25 38 calls and 4/4 weekly 37 puts are the most ...

Bearish flow noted in GSK (GSK) Pharma with 5,611 puts trading, or 3x expected. Most active are Mar-25 36.5 puts and 3/14 weekly 39.5 calls, with total volume in those strikes near 6,100 contracts.

Smith reminds investors that class action lawsuits ... and/or misleading statements and/or failed to disclose that: (1) GSK was fully aware of the source of NDMA and had been for nearly 40 years ...

GSK’s share price has fallen a long way from its one-year high, which has only increased the major undervaluation I’d seen in the stock before that. When investing, your capital is at risk ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other most undervalued biotech stocks to invest in. On February 21, Jared Holz, Mizuho Securities ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its plans to create a six-month regimen are shaping up. ViiV, which is ...